Purpose To investigate real-world prescribing trends and clinical outcomes based on body
mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This …

Cardiovascular disease (CVD) remains the leading cause of death in the USA. Several risk
factors have been identified, and obesity has become one of prominent concern. Excessive …

Introduction Venous thromboembolism (VTE) is a leading cause of morbidity and mortality
globally. The direct oral anticoagulants, including rivaroxaban, are relatively novel …

Background Emerging safety and efficacy data for rivaroxaban suggest traditional therapy
and rivaroxaban are comparable in the morbidly obese. However, real‐world data that …

The evidence of rivaroxaban's pharmacokinetics in obese compared with non‐obese
populations remains inconclusive. We aimed to compare the pharmacokinetic profile of …

Background Rivaroxaban, a direct oral anticoagulant (DOAC), has been shown to be an
efficacious and safe agent for treatment and secondary prevention of thromboembolism …

Abstract Background and Objective Rivaroxaban and apixaban are direct oral
anticoagulants increasing in popularity as convenient alternatives to warfarin. However …

The health implications of obesity are myriad and multifaceted. Physiologic changes
associated with obesity can affect the absorption, distribution, metabolism, and excretion of …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …